

Comprehensive Genomic Analysis Identifies Novel Subtypes of Breast Cancer

Clinical Cancer Research

21, 1688-1698

DOI: [10.1158/1078-0432.ccr-14-0432](https://doi.org/10.1158/1078-0432.ccr-14-0432)

Citation Report

#	ARTICLE	IF	CITATIONS
1	miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer. International Journal of Molecular Sciences, 2015, 16, 28347-28376.	1.8	56
2	Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues. PLoS ONE, 2015, 10, e0126762.	1.1	18
3	Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients. PLoS ONE, 2015, 10, e0128368.	1.1	58
4	Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer. BioMed Research International, 2015, 2015, 1-10.	0.9	87
5	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget, 2015, 6, 12890-12908.	0.8	92
6	Prognostic and predictive immune gene signatures in breast cancer. Current Opinion in Oncology, 2015, 27, 433-444.	1.1	75
7	Potential Therapeutic Targets in Triple Negative Breast Cancer. Current Breast Cancer Reports, 2015, 7, 215-223.	0.5	1
8	Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Hormones and Cancer, 2015, 6, 206-213.	4.9	88
9	Deptor Enhances Triple-Negative Breast Cancer Metastasis and Chemoresistance through Coupling to Survivin Expression. Neoplasia, 2015, 17, 317-328.	2.3	58
10	Mouse mammary stem cells express prognostic markers for triple-negative breast cancer. Breast Cancer Research, 2015, 17, 31.	2.2	35
11	Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Research, 2015, 17, 43.	2.2	248
12	Targeting thyroid hormone receptor beta in triple-negative breast cancer. Breast Cancer Research and Treatment, 2015, 150, 535-545.	1.1	31
13	Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends in Pharmacological Sciences, 2015, 36, 822-846.	4.0	242
14	Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast, 2015, 24, S36-S40.	0.9	108
15	Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers. Breast Cancer Research and Treatment, 2015, 154, 13-22.	1.1	62
16	Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast, 2015, 24, S26-S35.	0.9	735
17	Translating the Molecular Message of Triple-Negative Breast Cancer into Targeted Therapy. Clinical Cancer Research, 2015, 21, 1511-1513.	3.2	6
18	RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data Mining. International Journal of Genomics, 2016, 2016, 1-10.	0.8	15

#	ARTICLE	IF	CITATIONS
19	The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 34-42.	1.8	85
20	Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. <i>Oncotarget</i> , 2016, 7, 69903-69915.	0.8	60
21	Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 205.	1.3	35
22	Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. <i>PLoS ONE</i> , 2016, 11, e0157368.	1.1	975
23	A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways. <i>PLoS ONE</i> , 2016, 11, e0167397.	1.1	9
24	Molecular Classification of Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2016, 19, 223.	0.8	111
25	Triple-negative breast cancer: treatment challenges and solutions. <i>Breast Cancer: Targets and Therapy</i> , 2016, 8, 93.	1.0	201
26	CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. <i>Oncotarget</i> , 2016, 7, 69649-69665.	0.8	29
27	PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. <i>SpringerPlus</i> , 2016, 5, 805.	1.2	61
28	Triple negative breast cancer: Deciphering the biology and heterogeneity. <i>Medicina Universitaria</i> , 2016, 18, 105-114.	0.1	20
29	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 547-573.	2.7	189
30	Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 336-342.	0.5	9
31	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. <i>Modern Pathology</i> , 2016, 29, 476-488.	2.9	95
32	Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 33.	2.2	176
33	Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells. <i>Molecular Cancer</i> , 2016, 15, 34.	7.9	57
34	Validated biomarkers: The key to precision treatment in patients with breast cancer. <i>Breast</i> , 2016, 29, 192-201.	0.9	47
35	Dual roles of CCN proteins in breast cancer progression. <i>Journal of Cell Communication and Signaling</i> , 2016, 10, 217-222.	1.8	23
36	The calcium pump plasma membrane Ca ²⁺ -ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin. <i>Scientific Reports</i> , 2016, 6, 25505.	1.6	53

#	ARTICLE	IF	CITATIONS
37	The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. <i>Npj Breast Cancer</i> , 2016, 2, 16022.	2.3	21
38	Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. <i>Current Opinion in Pharmacology</i> , 2016, 31, 97-103.	1.7	126
39	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. <i>Npj Breast Cancer</i> , 2016, 2, 16036.	2.3	127
40	Targeting the androgen receptor in triple-negative breast cancer. <i>Current Problems in Cancer</i> , 2016, 40, 141-150.	1.0	70
41	Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer. <i>Pharmacological Research</i> , 2016, 111, 577-591.	3.1	46
42	Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy. <i>Scientific Reports</i> , 2016, 6, 30934.	1.6	29
43	Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.S34540.	0.6	121
44	Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival. <i>Radiology</i> , 2016, 281, 392-400.	3.6	100
45	Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer. <i>Human Pathology</i> , 2016, 55, 190-195.	1.1	19
47	PI3K-AKT-mTOR Pathway Cooperates with the DNA Damage Repair Pathway: Carcinogenesis in Triple-Negative Breast Cancers and Beyond. <i>Cancer Drug Discovery and Development</i> , 2016, , 65-108.	0.2	0
48	Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 39-50.	1.5	11
49	Expression of ROR1 has prognostic significance in triple negative breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 589-595.	1.4	63
50	IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. <i>Trends in Immunology</i> , 2016, 37, 193-207.	2.9	767
51	Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 593-607.	1.9	54
52	Chemokine axes in breast cancer: factors of the tumor microenvironment reshape the CCR7-driven metastatic spread of luminal-A breast tumors. <i>Journal of Leukocyte Biology</i> , 2016, 99, 1009-1025.	1.5	30
53	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. <i>Nature</i> , 2016, 529, 413-417.	13.7	490
54	miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016, 76, 927-939.	0.4	128
55	Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models. <i>Clinical Cancer Research</i> , 2016, 22, 923-934.	3.2	43

#	ARTICLE	IF	CITATIONS
56	Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis. <i>Oncolmmunology</i> , 2016, 5, e1061176.	2.1	30
57	Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications. <i>Current Breast Cancer Reports</i> , 2017, 9, 34-44.	0.5	11
58	Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 21-35.	1.1	102
59	Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers. <i>Cancer Immunology Research</i> , 2017, 5, 330-344.	1.6	28
60	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. <i>Oncolmmunology</i> , 2017, 6, e1253654.	2.1	146
61	Androgen receptor-positive, triple-negative breast cancer. <i>Cancer</i> , 2017, 123, 1686-1688.	2.0	14
62	The MicroRNA miR-210 Is Expressed by Cancer Cells but Also by the Tumor Microenvironment in Triple-Negative Breast Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2017, 65, 335-346.	1.3	30
63	Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. <i>Scientific Reports</i> , 2017, 7, 1089.	1.6	19
64	Basal-like breast cancer: molecular profiles, clinical features and survival outcomes. <i>BMC Medical Genomics</i> , 2017, 10, 19.	0.7	79
65	Reply to "Are all basal-like breast cancers associated with worse prognosis?". <i>Breast</i> , 2017, 33, 201.	0.9	0
66	Novel therapeutic strategies in the treatment of triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 493-511.	1.4	58
67	Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. <i>Oncologist</i> , 2017, 22, 1086-1093.	1.9	77
68	Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?. <i>Clinical Cancer Research</i> , 2017, 23, 2611-2616.	3.2	18
69	Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening. <i>Stem Cells</i> , 2017, 35, 1898-1912.	1.4	13
70	Centrosome amplification: a suspect in breast cancer and racial disparities. <i>Endocrine-Related Cancer</i> , 2017, 24, T47-T64.	1.6	15
71	Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge. , 2017, 179, 111-126.		57
72	TRPC1 is a differential regulator of hypoxia-mediated events and Akt signaling in PTEN-deficient breast cancer cells. <i>Journal of Cell Science</i> , 2017, 130, 2292-2305.	1.2	69
73	Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5561-5572.	3.2	198

#	ARTICLE	IF	CITATIONS
74	Wnt signaling in triple-negative breast cancer. <i>Oncogenesis</i> , 2017, 6, e310-e310.	2.1	217
75	NF- κ B Is a Potential Molecular Drug Target in Triple-Negative Breast Cancers. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 225-231.	1.0	47
76	Health Disparities and Triple-Negative Breast Cancer in African American Women. <i>JAMA Surgery</i> , 2017, 152, 485.	2.2	234
77	New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 490-498.	1.2	40
78	Biological Subtypes of Triple-Negative Breast Cancer. <i>Breast Care</i> , 2017, 12, 8-14.	0.8	85
79	A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 241-254.	1.1	21
80	Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. <i>Lancet, The</i> , 2017, 389, 2430-2442.	6.3	640
81	Molecular classification of breast cancer: what the pathologist needs to know. <i>Pathology</i> , 2017, 49, 111-119.	0.3	83
82	Triple-negative breast cancer and the potential for targeted therapy. <i>Pharmacogenomics</i> , 2017, 18, 1595-1609.	0.6	165
83	Targeting triple negative breast cancer with histone deacetylase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1199-1206.	1.9	58
84	How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. <i>ESMO Open</i> , 2017, 2, e000208.	2.0	47
85	A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. <i>Nature Genetics</i> , 2017, 49, 1476-1486.	9.4	427
86	Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. <i>Drug Resistance Updates</i> , 2017, 32, 1-15.	6.5	132
87	Breast Cancer Molecular Stratification. <i>American Journal of Pathology</i> , 2017, 187, 2152-2162.	1.9	198
88	The Spectrum of Triple-Negative Breast Disease. <i>American Journal of Pathology</i> , 2017, 187, 2139-2151.	1.9	118
89	Triple-Negative Breast Cancer. <i>American Journal of Pathology</i> , 2017, 187, 2133-2138.	1.9	60
90	The stem cell factor (SCF)/c-KIT system in carcinogenesis of reproductive tissues: What does the hormonal regulation tell us?. <i>Cancer Letters</i> , 2017, 405, 10-21.	3.2	14
91	The immune contexture in cancer prognosis and treatment. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 717-734.	12.5	1,590

#	ARTICLE	IF	CITATIONS
92	Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer. <i>Journal of Surgical Research</i> , 2017, 220, 46-51.	0.8	13
93	Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2017, 11, 117822341773156.	0.6	36
94	Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 13792-13797.	3.3	93
95	Genotranscriptomic meta-analysis of the CHD family chromatin remodelers in human cancers – initial evidence of an oncogenic role for CHD7. <i>Molecular Oncology</i> , 2017, 11, 1348-1360.	2.1	28
96	De-escalating and escalating systemic therapy in triple negative breast cancer. <i>Breast</i> , 2017, 34, S112-S115.	0.9	12
97	Identification of Interacting Stromal Axes in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2017, 77, 4673-4683.	0.4	25
98	Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). <i>Breast</i> , 2017, 34, S27-S30.	0.9	107
99	Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer. <i>Molecular BioSystems</i> , 2017, 13, 42-55.	2.9	19
100	MMTV-cre;Ccn6 knockout mice develop tumors recapitulating human metaplastic breast carcinomas. <i>Oncogene</i> , 2017, 36, 2275-2285.	2.6	23
101	Pathology and Molecular Pathology of Breast Cancer. , 2017, , 173-231.		1
102	Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, e65-e75.	1.1	14
103	Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 59-104.	0.8	46
104	Treating Triple Negative ABC. <i>Breast</i> , 2017, 36, S30-S31.	0.9	0
105	Up-modulation of PLC- β 2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133+/EpCAM+ phenotype: a promising target for preventing progression of TNBC. <i>BMC Cancer</i> , 2017, 17, 617.	1.1	24
106	Fatty acid metabolism in breast cancer subtypes. <i>Oncotarget</i> , 2017, 8, 29487-29500.	0.8	150
107	PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer. <i>Molecules</i> , 2017, 22, 2277.	1.7	12
108	Tackling intra- and inter-tumor heterogeneity to combat triple negative breast cancer. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 1549-1580.	3.0	14
109	The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas. <i>Cancers</i> , 2017, 9, 134.	1.7	101

#	ARTICLE	IF	CITATIONS
110	Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities. <i>Cancer & Metabolism</i> , 2017, 5, 6.	2.4	133
111	PD-L1 and intratumoral immune response in breast cancer. <i>Oncotarget</i> , 2017, 8, 51641-51651.	0.8	37
112	Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype. <i>Oncotarget</i> , 2017, 8, 73329-73344.	0.8	64
113	Basic Concepts in Molecular Pathologyâ€”Introduction to Molecular Testing in Human Disease. , 2017, , 3-14.		0
114	Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2017, 8, 124-130.	1.2	28
115	Practical Approach to Triple-Negative Breast Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, 293-300.	2.5	63
116	Novel Targeted Agents and Immunotherapy in Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 65-75.	1.8	8
117	Expression of <scp>MAGE</scp>â€”A and <scp>NY</scp>â€”<scp>ESO</scp>â€”1 cancer/testis antigens is enriched in tripleâ€”negative invasive breast cancers. <i>Histopathology</i> , 2018, 73, 68-80.	1.6	34
118	Overview of metastatic disease of the central nervous system. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018, 149, 3-23.	1.0	28
119	Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. <i>Clinical Cancer Research</i> , 2018, 24, 1845-1852.	3.2	84
120	An update on first line therapies for metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 243-252.	0.9	8
121	Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. <i>Annals of Oncology</i> , 2018, 29, 895-902.	0.6	245
123	Triple-Negative Breast Cancer. , 2018, , .		0
124	Molecular Profiling and Targeted Therapy for Triple-Negative Breast Cancer. , 2018, , 117-140.		0
125	Using gene expression data to direct breast cancer therapy: evidence from a preclinical trial. <i>Journal of Molecular Medicine</i> , 2018, 96, 111-117.	1.7	6
126	The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. <i>Cancer Treatment Reviews</i> , 2018, 67, 34-44.	3.4	71
127	Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. <i>Nature Medicine</i> , 2018, 24, 628-637.	15.2	649
128	MicroRNA-384 inhibits the progression of breast cancer by targeting ACVR1. <i>Oncology Reports</i> , 2018, 39, 2563-2574.	1.2	29

#	ARTICLE	IF	CITATIONS
129	Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers. <i>Clinical Breast Cancer</i> , 2018, 18, e1123-e1132.	1.1	36
130	The cellular and molecular effects of the androgen receptor agonist, CI-4AS-1, on breast cancer cells. <i>Endocrine Research</i> , 2018, 43, 203-214.	0.6	7
131	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 351-360.	1.1	5
132	Triple negative breast cancer: are we scoring a home run?. <i>Future Oncology</i> , 2018, 14, 793-796.	1.1	2
133	Triple-negative breast cancers – a panoply of cancer types. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 347-348.	12.5	45
134	Rationale for immunological approaches to breast cancer therapy. <i>Breast</i> , 2018, 37, 187-195.	0.9	23
135	The emerging world of breast cancer immunotherapy. <i>Breast</i> , 2018, 37, 200-206.	0.9	39
136	Identification of differentially expressed genes regulated by molecular signature in breast cancer-associated fibroblasts by bioinformatics analysis. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 161-183.	0.8	8
137	Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 459-468.	1.1	82
138	Synaptopodin ² suppresses metastasis of triple-negative breast cancer via inhibition of YAP/TAZ activity. <i>Journal of Pathology</i> , 2018, 244, 71-83.	2.1	40
139	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. <i>Pathology and Oncology Research</i> , 2018, 24, 701-716.	0.9	17
140	Breast Cancer Disparities. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 217-234.	0.6	22
141	Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	12
142	Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 65-77.	1.8	11
143	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 543-553.	0.8	162
144	Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 523-524.	0.8	2
145	LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers. <i>Oncotarget</i> , 2018, 9, 22586-22604.	0.8	21
146	Long-Term Complete Response of an Androgen Receptor-Positive Triple-Negative Metastatic Breast Cancer to Abiraterone Acetate. <i>JCO Precision Oncology</i> , 2018, 2, 0-0.	1.5	3

#	ARTICLE	IF	CITATIONS
147	TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities. <i>Pharmaceuticals</i> , 2018, 11, 123.	1.7	36
148	Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 179-190.	0.9	37
149	Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC). <i>Current Breast Cancer Reports</i> , 2018, 10, 282-288.	0.5	1
150	Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2018, 9, 4627-4634.	1.2	26
151	Classification of triple-negative breast cancers based on Immunogenomic profiling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 327.	3.5	329
152	Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer. <i>Oncology Reports</i> , 2019, 41, 437-446.	1.2	26
153	Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 900.	1.1	15
154	Updates on Molecular Classification of Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2018, 10, 289-295.	0.5	1
155	The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge. <i>Journal of Breast Cancer</i> , 2018, 21, 233.	0.8	59
156	Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. <i>Oncotarget</i> , 2018, 9, 26406-26416.	0.8	136
157	Whole Genome Transcriptome Analysis of the Association between Obesity and Triple-Negative Breast Cancer in Caucasian Women. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2338.	1.2	19
158	Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFR ² aptamer. <i>Theranostics</i> , 2018, 8, 5178-5199.	4.6	48
159	Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer (Review). <i>Oncology Letters</i> , 2018, 16, 4984-4996.	0.8	27
160	A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. <i>Cell</i> , 2018, 174, 1373-1387.e19.	13.5	729
161	Proteomic Analysis Reveals That an Extract of the Plant <i>Lippia organoides</i> Suppresses Mitochondrial Metabolism in Triple-Negative Breast Cancer Cells. <i>Journal of Proteome Research</i> , 2018, 17, 3370-3383.	1.8	20
162	TTK promotes mesenchymal signaling via multiple mechanisms in triple negative breast cancer. <i>Oncogenesis</i> , 2018, 7, 69.	2.1	57
163	Identification of Key Genes and Pathways in Triple-Negative Breast Cancer by Integrated Bioinformatics Analysis. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	59
164	In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. <i>Nature Communications</i> , 2018, 9, 3501.	5.8	45

#	ARTICLE	IF	CITATIONS
165	How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. <i>ESMO Open</i> , 2018, 3, e000357.	2.0	112
166	Estrogen receptor-negative progesterone receptor-positive breast cancer – “Nobody's land” or just an artifact?. <i>Cancer Treatment Reviews</i> , 2018, 67, 78-87.	3.4	46
167	Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors. <i>Seminars in Cancer Biology</i> , 2018, 52, 253-258.	4.3	12
168	NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. <i>Oncogenesis</i> , 2018, 7, 42.	2.1	39
169	Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. <i>Genes and Diseases</i> , 2018, 5, 77-106.	1.5	714
170	Future applications of FGF/FGFR inhibitors in cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 861-872.	1.1	76
171	Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance. <i>Histopathology</i> , 2018, 73, 887-896.	1.6	62
172	Clinical and molecular aspects of breast cancer: Targets and therapies. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 14-34.	2.5	49
173	Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes. <i>Molecular Cancer Research</i> , 2018, 16, 1889-1901.	1.5	68
174	ALMp1 Potentiates TH1 Polarization and Is Critical for Effective Antitumor and Antiviral Immunity. <i>Frontiers in Immunology</i> , 2017, 8, 1801.	2.2	28
175	Immune Landscape of Breast Cancers. <i>Biomedicines</i> , 2018, 6, 20.	1.4	81
176	The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer. <i>Genes</i> , 2018, 9, 29.	1.0	21
177	Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer. <i>Surgical Clinics of North America</i> , 2018, 98, 773-785.	0.5	10
178	Advances in the Systemic Treatment of Triple-Negative Breast Cancer. <i>Current Oncology</i> , 2018, 25, 142-150.	0.9	241
179	Applications of RNA Indexes for Precision Oncology in Breast Cancer. <i>Genomics, Proteomics and Bioinformatics</i> , 2018, 16, 108-119.	3.0	16
180	The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC). <i>BMC Cancer</i> , 2018, 18, 22.	1.1	23
181	The Critical, Clinical Role of Interferon-Beta in Regulating Cancer Stem Cell Properties in Triple-Negative Breast Cancer. <i>DNA and Cell Biology</i> , 2018, 37, 513-516.	0.9	9
182	Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. <i>Neoplasia</i> , 2018, 20, 951-963.	2.3	18

#	ARTICLE	IF	CITATIONS
183	Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer. <i>Cancer Investigation</i> , 2018, 36, 378-388.	0.6	8
184	The role of PDGF-B/PDGFR-BETA axis in the normal development and carcinogenesis of the breast. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 46-52.	2.0	29
185	Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification. <i>Cancer Research</i> , 2018, 78, 6001-6010.	0.4	64
186	Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer. <i>Scientific Reports</i> , 2018, 8, 11807.	1.6	43
187	The Effect of Perioperative Bevacizumab on Disease-Free and Overall Survival in Locally Advanced HER-2 Negative Breast Cancer: A Meta-Analysis. <i>Breast Cancer: Basic and Clinical Research</i> , 2018, 12, 117822341879225.	0.6	7
188	Triple-negative invasive breast carcinoma: the association between the sonographic appearances with clinicopathological feature. <i>Scientific Reports</i> , 2018, 8, 9040.	1.6	25
189	Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. <i>Cancer Treatment Reviews</i> , 2018, 68, 102-110.	3.4	183
190	Association between expression of random gene sets and survival is evident in multiple cancer types and may be explained by sub-classification. <i>PLoS Computational Biology</i> , 2018, 14, e1006026.	1.5	21
191	CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>Breast Cancer</i> , 2019, 26, 47-57.	1.3	7
192	Integrative 3â€² Untranslated Region-Based Model to Identify Patients with Low Risk of Axillary Lymph Node Metastasis in Operable Triple-Negative Breast Cancer. <i>Oncologist</i> , 2019, 24, 22-30.	1.9	13
193	Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 673-679.	1.1	37
194	Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers. <i>Breast Cancer Research</i> , 2019, 21, 85.	2.2	18
195	<p>Triple-negative breast cancer: current perspective on the evolving therapeutic landscape</p>. <i>International Journal of Women's Health</i> , 2019, Volume 11, 431-437.	1.1	117
196	Identification of Potential Crucial Genes and Key Pathways in Breast Cancer Using Bioinformatic Analysis. <i>Frontiers in Genetics</i> , 2019, 10, 695.	1.1	161
197	Expression of PD-L1 in primary breast carcinoma and lymph node metastases. <i>Surgical and Experimental Pathology</i> , 2019, 2, .	0.2	14
198	Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. <i>Cancers</i> , 2019, 11, 995.	1.7	53
199	Expression patterns of small numbers of transcripts from functionally-related pathways predict survival in multiple cancers. <i>BMC Cancer</i> , 2019, 19, 686.	1.1	8
200	Efficacy of Neoadjuvant <i>Versus</i> Adjuvant Chemotherapy in Hispanic/Latino (H/L) Women With Local or Locally Advanced Triple-negative Breast Cancer (TNBC). <i>In Vivo</i> , 2019, 33, 1227-1234.	0.6	9

#	ARTICLE	IF	CITATIONS
201	Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes. <i>Annals of Surgical Oncology</i> , 2019, 26, 3344-3353.	0.7	15
202	The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression. <i>Npj Breast Cancer</i> , 2019, 5, 22.	2.3	19
203	Molecular Classification and Prognostic Signatures of Breast Tumors. , 2019, , 129-138.		0
204	Advances in Targeted Therapies for Triple-Negative Breast Cancer. <i>Drugs</i> , 2019, 79, 1217-1230.	4.9	71
205	Identification of potential key genes and pathways predicting pathogenesis and prognosis for triple-negative breast cancer. <i>Cancer Cell International</i> , 2019, 19, 172.	1.8	31
206	4T1 Mammary Carcinoma Colonization of Metastatic Niches Is Accelerated by Obesity. <i>Frontiers in Oncology</i> , 2019, 9, 685.	1.3	25
207	Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2019, 22, 341.	0.8	39
208	<p>&integrated Bioinformatics Data Analysis Reveals Prognostic Significance Of SIDT1 In Triple-Negative Breast Cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8401-8410.	1.0	16
209	Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations. <i>Life Sciences</i> , 2019, 239, 117009.	2.0	142
210	Recent advances in nanotheranostics for triple negative breast cancer treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 430.	3.5	121
211	Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance. <i>BMC Cancer</i> , 2019, 19, 1039.	1.1	77
212	Balancing STAT Activity as a Therapeutic Strategy. <i>Cancers</i> , 2019, 11, 1716.	1.7	18
213	Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 119.	2.2	21
214	Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. , 2019, 7, 274.		26
215	Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer”How We Can Rise to the Challenge. <i>Cells</i> , 2019, 8, 957.	1.8	467
216	Breast Cancer Metastasis and Drug Resistance. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	38
217	Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 18295-18303.	3.3	82
218	Breast Cancer Heterogeneity in Primary and Metastatic Disease. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1152, 75-104.	0.8	27

#	ARTICLE	IF	CITATIONS
219	Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer. <i>Scientific Reports</i> , 2019, 9, 12492.	1.6	30
220	Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. <i>Cancers</i> , 2019, 11, 1334.	1.7	150
221	Breast cancer. <i>Nature Reviews Disease Primers</i> , 2019, 5, 66.	18.1	1,620
222	Whole genome sequencing of breast cancer. <i>Apmis</i> , 2019, 127, 303-315.	0.9	23
223	CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer. <i>BMC Cancer</i> , 2019, 19, 96.	1.1	60
224	Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. <i>Cancer Discovery</i> , 2019, 9, 176-198.	7.7	778
225	Therapeutic Potential of a Novel β 3 Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type. <i>Cancers</i> , 2019, 11, 139.	1.7	29
226	Cardiotoxicities of Modern Treatments in Breast Cancer. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 34.	0.4	2
227	Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis. <i>Advanced Science</i> , 2019, 6, 1802281.	5.6	50
228	Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 605-617.	0.8	28
229	Intrinsic Prognostic Impact of Tumor-infiltrating Lymphocytes in Systemically Untreated Patients With Early-stage Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 3111-3119.	0.5	12
230	LncRNA <i>HOTAIR</i> up-regulation is strongly related with lymph nodes metastasis and LAR subtype of Triple Negative Breast Cancer. <i>Journal of Cancer</i> , 2019, 10, 2018-2024.	1.2	51
231	Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications. <i>Breast Cancer Research</i> , 2019, 21, 65.	2.2	78
232	Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	192
233	Integration of transcriptomic data in a genome-scale metabolic model to investigate the link between obesity and breast cancer. <i>BMC Bioinformatics</i> , 2019, 20, 162.	1.2	22
234	The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 54.	2.2	57
235	Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?. <i>Stem Cell Investigation</i> , 2019, 6, 4-4.	1.3	1
236	Imaging features of triple-negative breast cancers according to androgen receptor status. <i>European Journal of Radiology</i> , 2019, 114, 167-174.	1.2	14

#	ARTICLE	IF	CITATIONS
237	PDLIM2 Is a Marker of Adhesion and β -Catenin Activity in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2019, 79, 2619-2633.	0.4	14
238	Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. <i>British Journal of Cancer</i> , 2019, 120, 913-921.	2.9	11
239	Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5002-5014.	3.2	269
240	Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. <i>Cancer Cell</i> , 2019, 35, 428-440.e5.	7.7	571
241	SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 293-302.	2.1	41
242	MicroRNAs and Androgen Receptor: Emerging Players in Breast Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 203.	1.1	19
243	Polymorphisms in CLDN1 are associated with age and differentiation of triple-negative breast cancer patients. <i>Bioscience Reports</i> , 2019, 39, .	1.1	5
244	Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes. <i>BMC Cancer</i> , 2019, 19, 215.	1.1	10
245	Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study. <i>EBioMedicine</i> , 2019, 42, 352-362.	2.7	35
246	LSECtin on tumor-associated macrophages enhances breast cancer stemness via interaction with its receptor BTN3A3. <i>Cell Research</i> , 2019, 29, 365-378.	5.7	44
247	A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 1902-1912.	2.3	37
248	Atypical Chemokine Receptor 1 (<i>DARC/ACKR1</i>) in Breast Tumors Is Associated with Survival, Circulating Chemokines, Tumor-Infiltrating Immune Cells, and African Ancestry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 690-700.	1.1	41
249	iTRAQ-Based Quantitative Proteomic Analysis Strengthens Transcriptomic Subtyping of Triple-Negative Breast Cancer Tumors. <i>Proteomics</i> , 2019, 19, 1800484.	1.3	14
250	A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses. <i>Scientific Reports</i> , 2019, 9, 1538.	1.6	46
251	ORAI1 and ORAI3 in Breast Cancer Molecular Subtypes and the Identification of ORAI3 as a Hypoxia Sensitive Gene and a Regulator of Hypoxia Responses. <i>Cancers</i> , 2019, 11, 208.	1.7	47
252	The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 667.	1.8	19
253	Therapeutic and Mechanistic Perspectives of Protein Complexes in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 335.	1.8	4
255	Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy Response. <i>Molecular Cancer Research</i> , 2020, 18, 253-263.	1.5	19

#	ARTICLE	IF	CITATIONS
256	Long noncoding RNA HAND2-AS1 restrains proliferation and metastasis of breast cancer cells through sponging miR-1275 and promoting SOX7. <i>Cancer Biomarkers</i> , 2019, 27, 85-94.	0.8	20
257	Androgen receptor and FOXA1 coexpression define a luminal-AR subtype of feline mammary carcinomas, spontaneous models of breast cancer. <i>BMC Cancer</i> , 2019, 19, 1267.	1.1	11
258	Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification. <i>Cancers</i> , 2019, 11, 1864.	1.7	5
259	Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. <i>PLoS ONE</i> , 2019, 14, e0224420.	1.1	36
260	Androgen receptor gene expression in primary breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 47.	2.3	29
261	Long intergenic noncoding RNA 299 methylation in peripheral blood is a biomarker for triple-negative breast cancer. <i>Epigenomics</i> , 2019, 11, 81-93.	1.0	32
262	Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers. <i>Molecular Cancer Research</i> , 2019, 17, 97-108.	1.5	17
263	Targeting triple negative breast cancer heterogeneity with chalcones: a molecular insight. <i>Journal of Drug Targeting</i> , 2019, 27, 830-838.	2.1	11
264	LRP8 is overexpressed in estrogen-negative breast cancers and a potential target for these tumors. <i>Cancer Medicine</i> , 2019, 8, 325-336.	1.3	18
265	Genomic Applications in Breast Carcinoma. , 2019, , 347-361.		0
266	Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells. <i>Oncogene</i> , 2019, 38, 2860-2875.	2.6	19
267	Immunological therapy: A novel thriving area for triple-negative breast cancer treatment. <i>Cancer Letters</i> , 2019, 442, 409-428.	3.2	41
268	Calcium signalling and breast cancer. <i>Seminars in Cell and Developmental Biology</i> , 2019, 94, 74-83.	2.3	58
269	Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran. <i>PLoS ONE</i> , 2019, 14, e0208701.	1.1	14
270	A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 605-613.	1.1	14
271	Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 29-42.	1.1	11
272	Comprehensive analysis of coexpressed long noncoding RNAs and genes in breast cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 428-437.	0.6	12
273	Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target. <i>Clinical Cancer Research</i> , 2019, 25, 856-867.	3.2	19

#	ARTICLE	IF	CITATIONS
274	Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 1838-1850.	3.2	41
275	Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 1-13.	1.1	21
276	Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET. <i>International Journal of Cancer</i> , 2019, 144, 651-664.	2.3	21
277	Does breast cancer growth rate really depend on tumor subtype? Measurement of tumor doubling time using serial ultrasonography between diagnosis and surgery. <i>Breast Cancer</i> , 2019, 26, 206-214.	1.3	32
278	Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT trial. <i>International Journal of Cancer</i> , 2020, 146, 262-271.	2.3	27
279	The role of SOX family members in solid tumours and metastasis. <i>Seminars in Cancer Biology</i> , 2020, 67, 122-153.	4.3	238
280	NCS-1 expression is higher in basal breast cancers and regulates calcium influx and cytotoxic responses to doxorubicin. <i>Molecular Oncology</i> , 2020, 14, 87-104.	2.1	7
281	Silencing of the cytokine receptor TNFRSF13B: A new therapeutic target for triple-negative breast cancer. <i>Cytokine</i> , 2020, 125, 154790.	1.4	13
282	Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis. <i>Methods in Molecular Biology</i> , 2020, 2055, 521-562.	0.4	33
283	Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach. <i>Journal of the National Cancer Institute</i> , 2020, 112, 708-719.	3.0	111
284	Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts. <i>Clinical Cancer Research</i> , 2020, 26, 657-668.	3.2	70
285	Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2020, 16, 4439-4453.	1.1	29
286	Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C γ Pathway in a Subset of Triple-Negative Breast Cancers. <i>American Journal of Pathology</i> , 2020, 190, 484-502.	1.9	15
287	Triple negative breast cancer: A thorough review of biomarkers. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 145, 102855.	2.0	153
288	Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations. <i>Modern Pathology</i> , 2020, 33, 1041-1055.	2.9	39
289	Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 423-433.	0.8	240
290	Molecular Classification of Breast Cancer. <i>Advances in Anatomic Pathology</i> , 2020, 27, 27-35.	2.4	283
291	Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples. <i>British Journal of Cancer</i> , 2020, 122, 397-404.	2.9	9

#	ARTICLE	IF	CITATIONS
292	Clustering and variable selection evaluation of 13 unsupervised methods for multi-omics data integration. <i>Briefings in Bioinformatics</i> , 2020, 21, 2011-2030.	3.2	54
293	Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020. <i>Breast Journal</i> , 2020, 26, 69-80.	0.4	31
294	A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer Medicine. <i>Cancers</i> , 2020, 12, 2811.	1.7	0
295	CRISPR-Cas9 Genome-Wide Knockout Screen Identifies Mechanism of Selective Activity of Dehydrofalcariol in Mesenchymal Stem-like Triple-Negative Breast Cancer Cells. <i>Journal of Natural Products</i> , 2020, 83, 3080-3092.	1.5	13
296	Claudin 1 inhibits cell migration and increases intercellular adhesion in triple-negative breast cancer cell line. <i>Molecular Biology Reports</i> , 2020, 47, 7643-7653.	1.0	10
297	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. <i>Npj Breast Cancer</i> , 2020, 6, 54.	2.3	181
298	Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 575-584.	1.1	5
299	Pristimerin exerts antitumor activity against MDA-MB-231 triple-negative breast cancer cells by reversing of epithelial-mesenchymal transition via downregulation of integrin β 3. <i>Biomedical Journal</i> , 2021, 44, S84-S92.	1.4	8
300	Expression of IFN-induced 2'-5'-oligoadenylate synthetases correlates with immune infiltration, revealing potential targets and new biomarkers for basal-like breast cancer prognosis. <i>International Immunopharmacology</i> , 2020, 88, 106916.	1.7	4
301	Epigenetic Regulation and Dietary Control of Triple Negative Breast Cancer. <i>Frontiers in Nutrition</i> , 2020, 7, 159.	1.6	7
302	Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer. <i>Current Medical Research and Opinion</i> , 2020, 36, 2025-2036.	0.9	5
303	Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1787.	1.3	25
304	Retyping of triple-negative breast cancer based on clustering method. <i>Expert Systems</i> , 2020, , e12583.	2.9	1
305	Triple-Negative Breast Cancer Cells Exhibit Differential Sensitivity to Cardenolides from <i>Calotropis gigantea</i> . <i>Journal of Natural Products</i> , 2020, 83, 2269-2280.	1.5	17
306	Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 2733-2745.	0.9	14
307	Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382094324.	0.8	5
308	A Novel Inhibitor of Carbonic Anhydrases Prevents Hypoxia-Induced TNBC Cell Plasticity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8405.	1.8	14
309	Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives. <i>International Journal of Breast Cancer</i> , 2020, 2020, 1-9.	0.6	7

#	ARTICLE	IF	CITATIONS
310	Signaling pathways essential for triple-negative breast cancer stem-like cells. <i>Stem Cells</i> , 2021, 39, 133-143.	1.4	26
311	Quadruple-negative breast cancer: novel implications for a new disease. <i>Breast Cancer Research</i> , 2020, 22, 127.	2.2	17
312	Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic. <i>Genes</i> , 2020, 11, 1367.	1.0	5
313	Immunological classification of gliomas based on immunogenomic profiling. <i>Journal of Neuroinflammation</i> , 2020, 17, 360.	3.1	17
314	Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype. <i>Cancers</i> , 2020, 12, 3298.	1.7	15
315	MALAT-1: LncRNA ruling miR-182/PIC-C/mesothelin triad in triple negative breast cancer. <i>Pathology Research and Practice</i> , 2020, 216, 153274.	1.0	10
316	Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8905.	1.8	30
317	Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors. <i>Cancers</i> , 2020, 12, 2012.	1.7	13
318	Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1083.	1.3	10
319	A Six-Epithelial Mesenchymal Transition Gene Signature May Predict Metastasis of Triple-Negative Breast Cancer. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6497-6509.	1.0	7
320	Effects of Cancer Stem Cells in Triple-Negative Breast Cancer and Brain Metastasis: Challenges and Solutions. <i>Cancers</i> , 2020, 12, 2122.	1.7	18
321	Pathological role of ion channels and transporters in the development and progression of triple-negative breast cancer. <i>Cancer Cell International</i> , 2020, 20, 377.	1.8	9
322	Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies. <i>Cells</i> , 2020, 9, 1855.	1.8	20
323	Tumor-Associated Neutrophils and Macrophages Heterogenous but Not Chaotic. <i>Frontiers in Immunology</i> , 2020, 11, 553967.	2.2	53
324	Local Disease-Free Survival Rate (LSR) Application to Personalize Radiation Therapy Treatments in Breast Cancer Models. <i>Journal of Personalized Medicine</i> , 2020, 10, 177.	1.1	3
325	Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth. <i>Oncogene</i> , 2020, 39, 6245-6262.	2.6	5
326	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. <i>Cancers</i> , 2020, 12, 2392.	1.7	171
327	Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers. <i>Theranostics</i> , 2020, 10, 10531-10547.	4.6	27

#	ARTICLE	IF	CITATIONS
328	Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials. <i>Cancers</i> , 2020, 12, 2497.	1.7	17
329	Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 325-334.	1.1	18
330	Mass Spectrometry-Based Omics for the Characterization of Triple-Negative Breast Cancer Bio-Signature. <i>Journal of Personalized Medicine</i> , 2020, 10, 277.	1.1	7
331	Development and validation of a prognostic nomogram for patients with triple-negative breast cancer with histology of infiltrating duct carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1447-1447.	0.7	4
332	M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome. <i>Frontiers in Immunology</i> , 2020, 11, 560074.	2.2	18
333	Characteristics and Prognosis of Triple-Negative Breast Cancer Patients: a Croatian Single Institution Retrospective Cohort Study. <i>Acta Clinica Croatica</i> , 2020, 59, 97-108.	0.1	8
334	Drug Repurposing for Triple-Negative Breast Cancer. <i>Journal of Personalized Medicine</i> , 2020, 10, 200.	1.1	29
335	Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication. <i>Genes and Genomics</i> , 2020, 42, 1381-1387.	0.5	23
336	Implications of BRCA Germline Mutations on Breast Cancer Medical Treatment. <i>Current Breast Cancer Reports</i> , 2020, 12, 59-65.	0.5	0
338	Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies. <i>Cancer</i> , 2020, 126, 3209-3218.	2.0	23
339	A novel prognostic two-gene signature for triple negative breast cancer. <i>Modern Pathology</i> , 2020, 33, 2208-2220.	2.9	22
340	The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors. <i>PLoS ONE</i> , 2020, 15, e0231999.	1.1	36
341	Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. <i>Oncologist</i> , 2020, 25, e1481-e1491.	1.9	92
342	Effects of folic acid withdrawal on transcriptomic profiles in murine triple-negative breast cancer cell lines. <i>Biochimie</i> , 2020, 173, 114-122.	1.3	7
343	Triple-negative breast cancer molecular subtyping and treatment progress. <i>Breast Cancer Research</i> , 2020, 22, 61.	2.2	1,022
344	Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, e108.	13.9	34
345	Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges. <i>Cancers</i> , 2020, 12, 1404.	1.7	78
346	Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance. <i>Molecular Cancer Research</i> , 2020, 18, 1257-1270.	1.5	86

#	ARTICLE	IF	CITATIONS
347	NEK10 tyrosine phosphorylates p53 and controls its transcriptional activity. <i>Oncogene</i> , 2020, 39, 5252-5266.	2.6	12
348	Leucinostatins from <i>Ophiocordyceps</i> spp. and <i>Purpureocillium</i> spp. Demonstrate Selective Antiproliferative Effects in Cells Representing the Luminal Androgen Receptor Subtype of Triple Negative Breast Cancer. <i>Journal of Natural Products</i> , 2020, 83, 2010-2024.	1.5	10
349	Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features. <i>Breast Care</i> , 2020, 15, 208-216.	0.8	6
350	Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 719.	1.7	15
351	Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090909.	1.4	14
352	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 18.	1.3	72
353	Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. <i>Cancers</i> , 2020, 12, 819.	1.7	61
354	Tumor Microenvironment. <i>Cancer Treatment and Research</i> , 2020, , .	0.2	12
355	An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers. <i>BMC Cancer</i> , 2020, 20, 197.	1.1	24
356	Molecular analysis of Chinese oesophageal squamous cell carcinoma identifies novel subtypes associated with distinct clinical outcomes. <i>EBioMedicine</i> , 2020, 57, 102831.	2.7	11
357	Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer. <i>In Vivo</i> , 2020, 34, 1715-1727.	0.6	16
358	The evolving management of metastatic triple negative breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 229-237.	0.8	28
359	Early stage triple negative breast cancer: Management and future directions. <i>Seminars in Oncology</i> , 2020, 47, 201-208.	0.8	23
360	Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups. <i>Scientific Reports</i> , 2020, 10, 2914.	1.6	18
361	Quadruple-Negative Breast Cancer: An Uneven Playing Field. <i>JCO Global Oncology</i> , 2020, 6, 233-237.	0.8	8
362	FGFR3 signaling and function in triple negative breast cancer. <i>Cell Communication and Signaling</i> , 2020, 18, 13.	2.7	37
363	Characteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer. <i>Journal of Clinical Pathology</i> , 2020, 73, 147-153.	1.0	7
364	XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2019, 9, 1459.	1.3	38

#	ARTICLE	IF	CITATIONS
365	Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer. <i>Tumor Biology</i> , 2020, 42, 101042831990105.	0.8	10
366	Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial. <i>Clinical Cancer Research</i> , 2020, 26, 2603-2614.	3.2	20
367	Novel Aptamers Selected on Living Cells for Specific Recognition of Triple-Negative Breast Cancer. <i>IScience</i> , 2020, 23, 100979.	1.9	19
368	Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy. <i>Scientific Reports</i> , 2020, 10, 7349.	1.6	2
369	Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer. , 2020, 8, e000169.		62
370	Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. <i>PLoS ONE</i> , 2020, 15, e0231711.	1.1	11
371	Molecular subtypes and precision treatment of triple-negative breast cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 499-499.	0.7	64
372	Ultrasonographic appearance of triple-negative invasive breast carcinoma is associated with novel molecular subtypes based on transcriptomic analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 435-435.	0.7	11
373	A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 159-170.	3.2	2
374	Sequential analysis of transcript expression patterns improves survival prediction in multiple cancers. <i>BMC Cancer</i> , 2020, 20, 297.	1.1	5
375	New Advances in Molecular Breast Cancer Pathology. <i>Seminars in Cancer Biology</i> , 2021, 72, 102-113.	4.3	37
376	Anticancer and Apoptotic-Inducing Effects of Rutin-Chitosan Nanoconjugates in Triple Negative Breast Cancer Cells. <i>Journal of Cluster Science</i> , 2021, 32, 331-340.	1.7	18
377	Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma. <i>Seminars in Cancer Biology</i> , 2021, 72, 114-122.	4.3	27
378	Pathology of triple negative breast cancer. <i>Seminars in Cancer Biology</i> , 2021, 72, 136-145.	4.3	118
379	Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. <i>Cell Research</i> , 2021, 31, 178-186.	5.7	146
380	Problematic breast tumors reassessed in light of novel molecular data. <i>Modern Pathology</i> , 2021, 34, 38-47.	2.9	25
381	Development of an absolute assignment predictor for triple-negative breast cancer subtyping using machine learning approaches. <i>Computers in Biology and Medicine</i> , 2021, 129, 104171.	3.9	8
382	Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. <i>Cell Metabolism</i> , 2021, 33, 51-64.e9.	7.2	211

#	ARTICLE	IF	CITATIONS
383	Triple-negative breast cancer: promising prognostic biomarkers currently in development. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 135-148.	1.1	80
384	Altered gene expression in glycolysis-cholesterol synthesis axis correlates with outcome of triple-negative breast cancer. <i>Experimental Biology and Medicine</i> , 2021, 246, 560-571.	1.1	8
385	Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells. <i>Life Sciences</i> , 2021, 266, 118886.	2.0	28
386	Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review. <i>Clinical Genetics</i> , 2021, 99, 613-637.	1.0	42
387	Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer. <i>Oncologist</i> , 2021, 26, e382-e393.	1.9	27
388	Targeting CXCL12-CXCR4 Signaling Enhances Immune Checkpoint Blockade Therapy Against Triple Negative Breast Cancer. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 157, 105606.	1.9	12
389	A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2021, 26, 99-e217.	1.9	49
390	Triple-negative breast cancer: new treatment strategies in the era of precision medicine. <i>Science China Life Sciences</i> , 2021, 64, 372-388.	2.3	26
391	Research advances and new challenges in overcoming triple-negative breast cancer. , 2021, 4, 517-542.		11
392	Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 109-117.	2.3	10
393	Long Non-coding RNA BTG3-7:1 and JUND Co-regulate C21ORF91 to Promote Triple-Negative Breast Cancer Progress. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 605623.	1.6	0
394	RNA m6A Methylation Regulators Subclassify Luminal Subtype in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 611191.	1.3	8
396	An <i>In Silico</i> Analysis Identified FZD9 as a Potential Prognostic Biomarker in Triple-Negative Breast Cancer Patients. <i>The Journal of Breast Health</i> , 2021, 17, 42-52.	0.4	2
397	Current Biomarkers for Precision Medicine in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1187, 363-379.	0.8	1
398	Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 41-49.	1.0	26
399	Cancer stem cell transcriptome landscape reveals biomarkers driving breast carcinoma heterogeneity. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 89-98.	1.1	5
400	Overexpression of GLUT3 promotes metastasis of triple-negative breast cancer by modulating the inflammatory tumor microenvironment. <i>Journal of Cellular Physiology</i> , 2021, 236, 4669-4680.	2.0	31
401	circ_NOTCH3 Functions as a Protooncogene Competing With miR-205-5p, Modulating KLF12 Expression and Promoting the Development and Progression of Basal-Like Breast Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 602694.	1.3	9

#	ARTICLE	IF	CITATIONS
402	Classification and gene selection of triple-negative breast cancer subtype embedding gene connectivity matrix in deep neural network. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	26
403	The advance of adjuvant treatment for triple-negative breast cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	11
404	bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses. <i>Database: the Journal of Biological Databases and Curation</i> , 2021, 2021, .	1.4	81
405	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3404-3413.	3.2	10
406	Identification of vascular dementia and Alzheimer's disease hub genes expressed in the frontal lobe and temporal cortex by weighted co-expression network analysis and construction of a protein-protein interaction. <i>International Journal of Neuroscience</i> , 2022, 132, 1049-1060.	0.8	5
407	Deep Learning and Digital Pathology Power Precision Treatment of Triple-Negative Breast Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
408	Investigation of Candidate Genes and Pathways in Basal/TNBC Patients by Integrated Analysis. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110195.	0.8	7
409	A Machine Learning Approach to Differentiate Two Specific Breast Cancer Subtypes Using Androgen Receptor Pathway Genes. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110279.	0.8	5
410	Molecular analyses of triple-negative breast cancer in the young and elderly. <i>Breast Cancer Research</i> , 2021, 23, 20.	2.2	23
411	Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data. <i>Ecancermedicalscience</i> , 2021, 15, 1178.	0.6	5
412	Decision theory for precision therapy of breast cancer. <i>Scientific Reports</i> , 2021, 11, 4233.	1.6	3
413	Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1465-1475.	3.0	50
414	Effective inhibition of mitochondrial metabolism by Cryptotanshinone in MDA-MB231 cells : A Proteomic Analysis. <i>Current Proteomics</i> , 2021, 18, .	0.1	0
415	Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer Therapeutics. <i>Cells</i> , 2021, 10, 433.	1.8	5
416	Low-grade triple-negative breast carcinomas. A report of 2 cases and an update of current concepts. <i>Revista Espanola De Patologia</i> , 2022, 55, 26-35.	0.6	0
417	Advanced Approaches to Breast Cancer Classification and Diagnosis. <i>Frontiers in Pharmacology</i> , 2020, 11, 632079.	1.6	86
418	Androgen Receptor and PIM1 Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 147-156.	1.0	4
419	Novel therapeutic strategies for patients with metastatic triple-negative breast cancer. <i>Journal of Modern Oncology</i> , 2020, 22, 60-65.	0.1	2

#	ARTICLE	IF	CITATIONS
421	Rare Breast Cancer Subtypes. <i>Current Oncology Reports</i> , 2021, 23, 54.	1.8	15
422	Immune Cell Infiltration-Based Characterization of Triple-Negative Breast Cancer Predicts Prognosis and Chemotherapy Response Markers. <i>Frontiers in Genetics</i> , 2021, 12, 616469.	1.1	12
423	Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence. <i>Cancers</i> , 2021, 13, 1586.	1.7	9
424	Potential Effect of <i>Pseudevernia furfuracea</i> (L.) Zopf Extract and Metabolite Physodic Acid on Tumour Microenvironment Modulation in MCF-10A Cells. <i>Biomolecules</i> , 2021, 11, 420.	1.8	9
425	Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. <i>Cells</i> , 2021, 10, 648.	1.8	47
426	¹⁸ F-FLT PET/CT imaging for early monitoring response to CDK4/6 inhibitor therapy in triple negative breast cancer. <i>Annals of Nuclear Medicine</i> , 2021, 35, 600-607.	1.2	7
427	Co-dependency for MET and FGFR1 in basal triple-negative breast cancers. <i>Npj Breast Cancer</i> , 2021, 7, 36.	2.3	12
428	Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. <i>Modern Pathology</i> , 2021, 34, 1282-1296.	2.9	22
429	Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer. , 2021, 9, e002022.		40
430	Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2608.	1.8	13
431	Identification and development of an independent immune-related genes prognostic model for breast cancer. <i>BMC Cancer</i> , 2021, 21, 329.	1.1	5
432	New Insight into Triple-Negative Breast Cancer Therapy: The Potential Roles of Endoplasmic Reticulum Stress and Autophagy Mechanisms. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, 679-691.	0.9	3
433	An immunohistochemical panel of three small ubiquitin-like modifier genes predicts outcomes of patients with triple-negative breast cancer. <i>Gland Surgery</i> , 2021, 10, 1067-1084.	0.5	3
434	Emerging Therapeutics for Patients with Triple-Negative Breast Cancer. <i>Current Oncology Reports</i> , 2021, 23, 57.	1.8	30
435	Molecular subtyping and functional validation of TTK, TPX2, UBE2C, and LRP8 in sensitivity of TNBC to paclitaxel. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 601-614.	1.8	19
436	Targeting ubiquitin conjugating enzyme UbcH5b by a triterpenoid PC3-15 from <i>Schisandra</i> plants sensitizes triple-negative breast cancer cells to lapatinib. <i>Cancer Letters</i> , 2021, 504, 125-136.	3.2	10
437	Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 1642.	1.7	21
438	Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 387-395.	1.1	8

#	ARTICLE	IF	CITATIONS
439	Molecular Prognostic and Predictive Markers in Triple - Negative Breast Cancer. , 0, , .		2
440	Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 131-147.	1.0	5
441	Gene network analysis using SWIM reveals interplay between the transcription factorâ€encoding genes HMGA1, FOXM1, and MYBL2 in tripleâ€negative breast cancer. <i>FEBS Letters</i> , 2021, 595, 1569-1586.	1.3	12
442	Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers. <i>BMC Cancer</i> , 2021, 21, 644.	1.1	12
443	Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 323-337.	1.1	15
444	Tripleâ€negative breast cancer: A runâ€through of features, classification and currentâ therapies (Review). <i>Oncology Letters</i> , 2021, 22, 512.	0.8	52
445	Finding the positive in triple-negative breast cancer. <i>Nature Cancer</i> , 2021, 2, 476-478.	5.7	3
446	Construction and Identification of New Molecular Markers of Triple-Negative Breast Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2021, 11, 647291.	1.3	0
447	Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 625-633.	1.1	8
448	Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. , 2021, 9, e002198.		18
449	Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive. <i>Pharmaceuticals</i> , 2021, 14, 455.	1.7	18
450	Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women. <i>Human Pathology</i> , 2021, 111, 10-20.	1.1	8
451	Metastatic Triple Negative Breast Cancer: The New Era of Thinking. <i>Forum of Clinical Oncology</i> , 2021, .	0.1	0
452	A network approach reveals driver genes associated with survival of patients with triple-negative breast cancer. <i>IScience</i> , 2021, 24, 102451.	1.9	8
453	The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 69.	2.3	7
454	Genomic features of rapid versus late relapse in triple negative breast cancer. <i>BMC Cancer</i> , 2021, 21, 568.	1.1	10
455	CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers. <i>Cancers</i> , 2021, 13, 2328.	1.7	20
456	Engineering Breast Cancer On-chipâ€Moving Toward Subtype Specific Models. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 694218.	2.0	18

#	ARTICLE	IF	CITATIONS
457	The importance of androgen receptors in breast cancer. <i>Medicine and Pharmacy Reports</i> , 2021, 94, 273-281.	0.2	2
458	Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 537-547.	2.7	58
459	Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 605-611.	1.1	4
460	Triple negative breast cancer: emerging light on the horizon—a narrative review. <i>Precision Cancer Medicine</i> , 0, 4, 12-12.	1.8	1
461	Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 681476.	1.3	71
462	Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2978.	1.7	12
463	CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers. <i>Cancers</i> , 2021, 13, 2872.	1.7	45
464	Activity of trastuzumab emtansine (T-DM1) in 3D cell culture. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 65-75.	1.1	7
465	Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival. <i>Scientific Reports</i> , 2021, 11, 12541.	1.6	25
466	The Roles of DNA Demethylases in Triple-Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 628.	1.7	4
467	Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. <i>Journal of the National Cancer Institute</i> , 2022, 114, 664-675.	3.0	31
468	Time-Sequencing of the Neutrophil-to-Lymphocyte Ratio to Predict Prognosis of Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 3472.	1.7	10
471	Weighted gene co-expression network analysis of the association between upregulated AMD1, EN1 and VGLL1 and the progression and poor prognosis of breast cancer. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1030.	0.8	6
472	Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions. <i>Cancers</i> , 2021, 13, 3739.	1.7	27
473	Advances in Pathophysiology of Triple-Negative Breast Cancer: The Potential of lncRNAs for Clinical Diagnosis, Treatment, and Prognostic Monitoring. <i>Molecular Biotechnology</i> , 2021, 63, 1093-1102.	1.3	4
474	Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7154.	1.8	5
475	ETV7 regulates breast cancer stem-like cell features by repressing IFN-response genes. <i>Cell Death and Disease</i> , 2021, 12, 742.	2.7	16
476	Differential Regulation of Lacto-/Neolacto- Glycosphingolipid Biosynthesis Pathway Reveals Transcription Factors as Potential Candidates in Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 3330.	1.7	1

#	ARTICLE	IF	CITATIONS
478	Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models. <i>Breast Cancer Research</i> , 2021, 23, 82.	2.2	14
479	A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer. <i>Aging</i> , 2021, 13, 19486-19509.	1.4	28
480	A systematic review of datasets that can help elucidate relationships among gene expression, race, and immunohistochemistry-defined subtypes in breast cancer. <i>Cancer Biology and Therapy</i> , 2021, 22, 1-13.	1.5	2
481	Androgen receptor expression and prognosis in Hispanic/Latino women with triple negative breast cancer. <i>Revista Espanola De Patologia</i> , 2022, 55, 96-104.	0.6	2
482	Heterogeneity within molecular subtypes of breast cancer. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 321, C343-C354.	2.1	43
483	<i>In-Silico</i> Analysis of Differentially Expressed Genes and Their Regulating microRNA Involved in Lymph Node Metastasis in Invasive Breast Carcinoma. <i>Cancer Investigation</i> , 2022, 40, 55-72.	0.6	4
484	A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype. <i>Frontiers in Immunology</i> , 2021, 12, 749459.	2.2	30
485	Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. <i>European Journal of Cancer</i> , 2021, 154, 11-20.	1.3	34
486	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. <i>Npj Breast Cancer</i> , 2021, 7, 124.	2.3	7
487	A CTL/M2 macrophage-related four-gene signature predicting metastasis-free survival in triple-negative breast cancer treated with adjuvant radiotherapy. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 329-341.	1.1	5
488	Glucose Metabolism and Glucose Transporters in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 728759.	1.8	69
489	Prognostic Effect of Microenvironment Phenotype in Triple-Negative Breast Cancer: Biomarker Analysis of a Prospective Trial. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 752154.	1.6	2
490	Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 114.	2.3	3
491	A narrative review of biomarkers in advanced triple negative breast cancer. <i>Precision Cancer Medicine</i> , 0, 4, 24-24.	1.8	1
493	Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments. <i>Cancers</i> , 2021, 13, 4544.	1.7	11
494	Expression of LGR5 in mammary myoepithelial cells and in triple-negative breast cancers. <i>Scientific Reports</i> , 2021, 11, 17750.	1.6	4
495	Prediction for pathological and immunohistochemical characteristics of triple-negative invasive breast carcinomas: the performance comparison between quantitative and qualitative sonographic feature analysis. <i>European Radiology</i> , 2022, 32, 1590-1600.	2.3	7
496	Molecular Classification Models for Triple Negative Breast Cancer Subtype Using Machine Learning. <i>Journal of Personalized Medicine</i> , 2021, 11, 881.	1.1	5

#	ARTICLE	IF	CITATIONS
497	Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies. <i>Clinical Breast Cancer</i> , 2021, 21, 509-520.	1.1	13
498	Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy. <i>Advanced Science</i> , 2021, 8, e2100974.	5.6	15
499	Reducing variability of breast cancer subtype predictors by grounding deep learning models in prior knowledge. <i>Computers in Biology and Medicine</i> , 2021, 138, 104850.	3.9	4
500	Regulation of cancer stem cells in triple negative breast cancer. , 2021, 4, 321-342.		28
501	Triple Negative Breast Cancer. , 2022, , 35-48.		1
503	Sonographic Features of Triple-Negative Breast Carcinomas Are Correlated With mRNA-lncRNA Signatures and Risk of Tumor Recurrence. <i>Frontiers in Oncology</i> , 2020, 10, 587422.	1.3	7
504	NGS-based profiling of key cancer genes in Indian triple-negative breast cancer patients reinforces molecular heterogeneity of the disease. <i>Indian Journal of Cancer</i> , 2021, 58, 598-602.	0.2	0
505	YY1 is involved in the pathogenesis and malignant properties of human triple-negative breast cancer (TNBC). , 2021, , 149-162.		1
506	Prune-1 drives polarization of tumor-associated macrophages (TAMs) within the lung metastatic niche in triple-negative breast cancer. <i>IScience</i> , 2021, 24, 101938.	1.9	11
507	Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 2-7.	1.0	13
508	The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine. <i>Oncolmmunology</i> , 2021, 10, 1924492.	2.1	8
509	Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2021, 15, 117822342110024.	0.6	16
510	Development of Gene Expression-Based Biomarkers on the nCounter® Platform for Immuno-Oncology Applications. <i>Methods in Molecular Biology</i> , 2020, 2055, 273-300.	0.4	4
511	Triple-Negative Breast Cancer. , 2020, , 209-223.		1
512	Somatic mutations of triple-negative breast cancer: a comparison between Black and White women. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 503-509.	1.1	11
513	Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. <i>Drugs</i> , 2021, 81, 317-331.	4.9	173
514	Triple-Negative Breast Cancer, Stem Cells, and African Ancestry. <i>American Journal of Pathology</i> , 2018, 188, 271-279.	1.9	33
516	The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. <i>Nature Communications</i> , 2020, 11, 6433.	5.8	37

#	ARTICLE	IF	CITATIONS
517	Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis. <i>Biochemical Society Transactions</i> , 2020, 48, 657-665.	1.6	80
518	Innovations in targeted therapies for triple negative breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 34-47.	0.9	4
519	Molecular Subtyping of Triple Negative Breast Cancer by Surrogate Immunohistochemistry Markers. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 251-257.	0.6	9
522	Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. <i>Journal of Clinical Investigation</i> , 2019, 129, 1785-1800.	3.9	266
523	Genomic Alteration in Metastatic Breast Cancer and Its Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 30-43.	1.8	107
524	High Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0140572.	1.1	48
525	Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA. <i>PLoS ONE</i> , 2016, 11, e0160174.	1.1	14
526	Prolactin modulates TNBC aggressive phenotype limiting tumorigenesis. <i>Endocrine-Related Cancer</i> , 2019, 26, 321-337.	1.6	13
527	Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes. <i>Critical Reviews in Oncogenesis</i> , 2016, 21, 333-351.	0.2	44
528	Construction and validation of an immunity-related prognostic signature for breast cancer. <i>Aging</i> , 2020, 12, 21597-21612.	1.4	9
529	Identification of candidate genes associated with triple negative breast cancer. <i>Genes and Cancer</i> , 2017, 8, 659-672.	0.6	19
530	Using interferon-beta to combat cancer stem cell properties in triple negative breast cancer. <i>Oncoscience</i> , 2018, 5, 169-171.	0.9	2
531	Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. <i>Oncotarget</i> , 2016, 7, 48206-48219.	0.8	32
532	The effect of androgen receptor expression on clinical characterization of metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 8693-8706.	0.8	7
533	Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. <i>Oncotarget</i> , 2017, 8, 22218-22234.	0.8	46
534	Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response. <i>Oncotarget</i> , 2017, 8, 47400-47411.	0.8	21
535	Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways. <i>Oncotarget</i> , 2017, 8, 80568-80588.	0.8	61
536	Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. <i>Oncotarget</i> , 2017, 8, 70481-70495.	0.8	14

#	ARTICLE	IF	CITATIONS
537	The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 76974-76986.	0.8	34
538	Gene expression information improves reliability of receptor status in breast cancer patients. <i>Oncotarget</i> , 2017, 8, 77341-77359.	0.8	7
539	Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method. <i>Oncotarget</i> , 2017, 8, 92926-92942.	0.8	6
540	The TGF β -EGFR-Akt signaling axis plays a role in enhancing proinflammatory chemokines in triple-negative breast cancer cells. <i>Oncotarget</i> , 2018, 9, 29286-29303.	0.8	12
541	Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. <i>Oncotarget</i> , 2018, 9, 33912-33930.	0.8	39
542	Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity. <i>Oncotarget</i> , 2019, 10, 198-208.	0.8	32
543	Differential gene expression and AKT targeting in triple negative breast cancer. <i>Oncotarget</i> , 2019, 10, 4356-4368.	0.8	14
544	The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. <i>Oncotarget</i> , 2016, 7, 13106-13121.	0.8	63
545	The matricellular protein CCN6 (WISP3) decreases Notch1 and suppresses breast cancer initiating cells. <i>Oncotarget</i> , 2016, 7, 25180-25193.	0.8	23
546	Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5. <i>Oncotarget</i> , 2016, 7, 24495-24509.	0.8	105
547	BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer. <i>Current Drug Targets</i> , 2020, 21, 962-973.	1.0	8
548	Strategic Developments & Future Perspective on Gene Therapy for Breast Cancer: Role of mTOR and Brk/ PTK6 as Molecular Targets. <i>Current Gene Therapy</i> , 2020, 20, 237-258.	0.9	22
549	Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer. <i>Current Cancer Drug Targets</i> , 2020, 20, 586-602.	0.8	78
550	Immune Blockade Inhibition in Breast Cancer. <i>Anticancer Research</i> , 2016, 36, 5607-5622.	0.5	37
551	Tumor-Associated Neutrophils in Breast Cancer Subtypes. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 2689-2693.	0.5	31
552	Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer. <i>Life Science Alliance</i> , 2020, 3, e201900562.	1.3	11
553	An Integrative Genomics Approach for Associating Genetic Susceptibility with the Tumor Immune Microenvironment in Triple Negative Breast Cancer. <i>Biomedical Journal of Scientific & Technical Research</i> , 2019, 15, .	0.0	1
554	Histological and molecular classification of breast cancer: what do we know?. <i>Mastology</i> , 0, 30, .	0.1	48

#	ARTICLE	IF	CITATIONS
555	Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer. <i>Einstein (Sao Paulo, Brazil)</i> , 2019, 17, eAO3434.	0.3	7
556	Comprehensive identification and characterization of somatic copy number alterations in triple-negative breast cancer. <i>International Journal of Oncology</i> , 2020, 56, 522-530.	1.4	12
557	HSulfate ¹ and palbociclib exert synergistic antitumor effects on RB-positive triple-negative breast cancer. <i>International Journal of Oncology</i> , 2020, 57, 223-236.	1.4	8
558	Identification of key genes as potential biomarkers for triple-negative breast cancer using integrating genomics analysis. <i>Molecular Medicine Reports</i> , 2020, 21, 557-566.	1.1	16
559	Three-microRNA expression signature predicts survival in triple-negative breast cancer. <i>Oncology Letters</i> , 2020, 19, 301-308.	0.8	21
560	Circulating microRNAs and their role in the immune response in triple-negative breast cancer (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	13
561	Identification of a prognosis-associated signature associated with energy metabolism in triple-negative breast cancer. <i>Oncology Reports</i> , 2020, 44, 819-837.	1.2	14
562	Knockdown of SERPINE1 reverses resistance of triple-negative breast cancer to paclitaxel via suppression of VEGFA. <i>Oncology Reports</i> , 2020, 44, 1875-1884.	1.2	28
563	Genomic profiling of brain metastases: current knowledge and new frontiers. <i>Chinese Clinical Oncology</i> , 2015, 4, 22.	0.4	16
564	Cancer stem cells and early stage basal-like breast cancer. <i>World Journal of Obstetrics and Gynecology</i> , 2016, 5, 150.	0.5	5
565	Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. <i>Theranostics</i> , 2020, 10, 1531-1543.	4.6	34
566	Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 1008.	1.7	9
568	Molecular characterization of triple negative breast cancer formaldehyde-fixed paraffin-embedded samples by data-independent acquisition proteomics. <i>Proteomics</i> , 2022, 22, e2100110.	1.3	3
569	Expression of N-Terminal-Deficient E-Cadherin Protein in Invasive Lobular Carcinoma of the Breast. <i>American Journal of Surgical Pathology</i> , 2021, Publish Ahead of Print, .	2.1	2
570	Exosomal miRNA profiles of triple-negative breast cancer in neoadjuvant treatment. <i>Oncology Letters</i> , 2021, 22, 819.	0.8	24
571	Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression. <i>Npj Breast Cancer</i> , 2021, 7, 136.	2.3	20
572	Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping. <i>Breast Care</i> , 2021, 16, 637-647.	0.8	7
573	Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. <i>Npj Precision Oncology</i> , 2021, 5, 92.	2.3	11

#	ARTICLE	IF	CITATIONS
574	Biomarkers of immunotherapy response in breast cancer beyond PD-L1. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 39-49.	1.1	11
575	An Immune-Related Gene Prognostic Index for Triple-Negative Breast Cancer Integrates Multiple Aspects of Tumor-Immune Microenvironment. <i>Cancers</i> , 2021, 13, 5342.	1.7	15
576	Functional Proteomic Profiling of Triple-Negative Breast Cancer. <i>Cells</i> , 2021, 10, 2768.	1.8	10
577	Analyzing mRNAi-Related Genes Identifies Novel Prognostic Markers and Potential Drug Combination for Patients with Basal Breast Cancer. <i>Disease Markers</i> , 2021, 2021, 1-15.	0.6	6
578	Genomic Markers in ER-Negative Breast Cancer. , 2016, , 283-298.		0
579	Better Together: Immunotherapy as Future Combination Strategy for Breast Cancer. <i>Immunotherapy (Los Angeles, Calif)</i> , 2016, 02, .	0.1	0
580	Discoidin Domain Receptors in Normal Mammary Development and Breast Cancer Progression. , 2016, , 119-144.		0
581	Molecular Classification of Breast Cancer. , 2016, , 203-219.		2
582	Effect of Basal Subtype in Survival in Metastatic Breast Cancer Patients who Received First-Line Gemcitabine-Carboplatin after Receiving Anthracyclines and Taxanes in Adjuvant Phase. <i>Journal of Cancer Prevention & Current Research</i> , 2016, 5, .	0.1	0
583	Calcium Channels and Pumps: Importance During Lactation as Potential Targets for Breast Cancer. <i>Molecular and Integrative Toxicology</i> , 2017, , 1-17.	0.5	0
584	New Progress in Breast Cancer Immunotherapy. <i>Advances in Clinical Medicine</i> , 2018, 08, 47-52.	0.0	0
585	Basic Molecular Pathology in Breast Carcinoma. , 2018, , 357-372.		2
586	Relationship between tumor infiltrating lymphocytes and progression in triple negative breast cancer. <i>Ginecologia Ro</i> , 2018, 3, 28.	0.0	1
587	Breast Cancer Receptors and Targeting Strategies. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2019, , 79-108.	0.2	1
591	Clinical Behavior of Triple Negative Breast Cancer in a Cohort of Latin American Women  . <i>Cureus</i> , 2019, 11, e4963.	0.2	6
593	Third Line Eribulin for Triple-negative Metastatic Breast Ductal Carcinoma Resulting in Extended Progression-free Survival of 57 Months. <i>Cureus</i> , 2020, 12, e6980.	0.2	3
595	The modern views of the clinical, morphological and molecular biological predictors of breast cancer sensitivity to chemotherapy. <i>Uspehi Molekularnoj Onkologii</i> , 2020, 7, 20-28.	0.1	0
596	SMARCA4 Depletion Induces Cisplatin Resistance by Activating YAP1-Mediated Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 5474.	1.7	15

#	ARTICLE	IF	CITATIONS
597	Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype. <i>Cancers</i> , 2021, 13, 5348.	1.7	4
598	Aldehyde Dehydrogenase 1-related Genes in Triple-negative Breast Cancer Investigated Using Network Analysis. <i>Anticancer Research</i> , 2020, 40, 6733-6742.	0.5	2
599	The nature of triple-negative breast cancer classification and antitumoral strategies. <i>Genomics and Informatics</i> , 2020, 18, e35.	0.4	2
600	A Mechanistic Investigation on the Anticancer Properties of SYA013, a Homopiperazine Analogue of Haloperidol with Activity against Triple Negative Breast Cancer Cells. <i>ACS Omega</i> , 2020, 5, 32907-32918.	1.6	6
601	Sericin inhibits MDA-MB-468 cell proliferation via the PI3K/Akt pathway in triple-negative breast cancer. <i>Molecular Medicine Reports</i> , 2020, 23, .	1.1	12
603	The Immune Landscape in Women Cancers. <i>Cancer Treatment and Research</i> , 2020, 180, 215-249.	0.2	3
604	Platinum-based drugs in neoadjuvant treatment of patients with triple-negative breast cancer. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2020, 9, 62.	0.0	0
605	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. <i>Nature Communications</i> , 2021, 12, 6276.	5.8	89
606	Multiplexed immunofluorescence identifies high stromal CD68+PD-L1+ macrophages as a predictor of improved survival in triple negative breast cancer. <i>Scientific Reports</i> , 2021, 11, 21608.	1.6	16
609	Aberrations of the number of copies (CNA) in the genome of luminal B breast tumor. <i>Bulletin of Siberian Medicine</i> , 2020, 19, 22-28.	0.1	2
611	Breast cancer molecular subtypes: from TNBC to QNBC. <i>American Journal of Cancer Research</i> , 2016, 6, 1864-1872.	1.4	65
612	Triple Negative Breast Cancer at the University Hospital Mohammed VI "Oujda. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 195-200.	0.5	2
613	, , and genetic profile in Moroccan triple negative breast cancer cases. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2020, 11, 16-25.	0.4	1
614	The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3027-3032.	0.5	1
615	Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. <i>Current Scenario and Future Perspectives. Frontiers in Oncology</i> , 2021, 11, 769280.	1.3	45
616	The Large GTPase, GBP-2, Regulates Rho Family GTPases to Inhibit Migration and Invadosome Formation in Breast Cancer Cells. <i>Cancers</i> , 2021, 13, 5632.	1.7	4
617	Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer. <i>Medical Oncology</i> , 2022, 39, 14.	1.2	15
618	Treatment landscape of triple-negative breast cancer " expanded options, evolving needs. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 91-113.	12.5	414

#	ARTICLE	IF	CITATIONS
619	CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. <i>MedComm</i> , 2021, 2, 514-530.	3.1	12
620	PlntMF: Penalized Integrative Matrix Factorization method for multi-omics data. <i>Bioinformatics</i> , 2022, 38, 900-907.	1.8	5
621	Hsa-mir-3163 and CCNB1 may be potential biomarkers and therapeutic targets for androgen receptor positive triple-negative breast cancer. <i>PLoS ONE</i> , 2021, 16, e0254283.	1.1	9
622	Autophagy: A promising target for triple negative breast cancers. <i>Pharmacological Research</i> , 2022, 175, 106006.	3.1	20
623	Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer. <i>PeerJ</i> , 2021, 9, e12383.	0.9	7
624	The matricellular protein CCN6 differentially regulates mitochondrial metabolism in normal epithelium and in metaplastic breast carcinomas. <i>Journal of Cell Communication and Signaling</i> , 2022, 16, 433-445.	1.8	2
625	Triple-negative breast cancer and basal-like subtype: Pathology and targeted therapy. <i>Journal of Medical Investigation</i> , 2021, 68, 213-219.	0.2	7
627	The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3027-3032.	0.5	10
628	Management of triple-negative breast cancer in the era of novel therapies: A narrative review. <i>Cancer Research Statistics and Treatment</i> , 2021, 4, 668.	0.1	4
629	Mammary Tumor-Derived Transplants as Breast Cancer Models to Evaluate Tumor-Immune Interactions and Therapeutic Responses. <i>Cancer Research</i> , 2022, 82, 365-376.	0.4	1
630	Epigenetic Reprogramming and Landscape of Transcriptomic Interactions: Impending Therapeutic Interference of Triple-Negative Breast Cancer in Molecular Medicine. <i>Current Molecular Medicine</i> , 2022, 22, 835-850.	0.6	3
631	Prognostic Value of Metabolic, Volumetric and Textural Parameters of Baseline [18F]FDG PET/CT in Early Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 637.	1.7	17
632	Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1665.	1.8	48
633	Mapping Intellectual Structures and Research Hotspots of Triple Negative Breast Cancer: A Bibliometric Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 689553.	1.3	17
634	Establishing a competing endogenous RNA (ceRNA)-immunoregulatory network associated with the progression of Alzheimer's disease. <i>Annals of Translational Medicine</i> , 2022, 10, 65-65.	0.7	5
635	Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer. <i>Biomolecules</i> , 2022, 12, 72.	1.8	18
636	A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 599-610.	1.1	4
637	Applications of Extracellular Vesicles in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 451.	1.7	14

#	ARTICLE	IF	CITATIONS
638	Mouse Modeling Dissecting Macrophageâ€œBreast Cancer Communication Uncovered Roles of PYK2 in Macrophage Recruitment and Breast Tumorigenesis. <i>Advanced Science</i> , 2022, 9, e2105696.	5.6	14
639	Systemic treatment for triple negative breast cancer in older patients: A Young International Society of Geriatric Oncology Review Paper. <i>Journal of Geriatric Oncology</i> , 2022, , .	0.5	4
640	Fatty acid synthetase expression in triple-negative breast cancer. <i>Journal of Pathology and Translational Medicine</i> , 2022, , .	0.4	5
641	Pathogenesis of Triple-Negative Breast Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 181-204.	9.6	132
642	A Novel IGLC2 Gene Linked With Prognosis of Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 759952.	1.3	7
643	Terapia personalizada en cÃ¡ncer de mama precoz. Implicancias prÃ¡cticas. <i>Revista MÃ©dica ClÃnica Las Condes</i> , 2022, 33, 17-24.	0.2	0
644	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1323-1334.	0.8	62
645	Redox State and Gene Regulation in Breast Cancer. , 2022, , 1461-1480.		0
646	Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response. <i>Future Oncology</i> , 2022, 18, 1055-1066.	1.1	3
647	Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102352.	3.4	17
648	Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. <i>Cell Research</i> , 2022, 32, 477-490.	5.7	101
649	Update Breast Cancer 2021 Part 5 â€œ Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 215-225.	0.8	6
650	Quantitative single-cell analysis of immunofluorescence protein multiplex images illustrates biomarker spatial heterogeneity within breast cancer subtypes. <i>Breast Cancer Research</i> , 2021, 23, 114.	2.2	3
651	Lift the Veil of Breast Cancers Using 4 or Fewer Critical Genes. <i>Cancer Informatics</i> , 2022, 21, 117693512210763.	0.9	11
652	Diverse roles of tumor-stromal PDGFB-to-PDGFR ² signaling in breast cancer growth and metastasis. <i>Advances in Cancer Research</i> , 2022, 154, 93-140.	1.9	6
653	Emerging treatment strategies for metastatic triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210869.	1.4	15
654	YAP Dictates Mitochondrial Redox Homeostasis to Facilitate Obesityâ€œAssociated Breast Cancer Progression. <i>Advanced Science</i> , 2022, 9, e2103687.	5.6	7
655	The Association of RGS2 and Slug in the Androgen-induced Acquisition of Mesenchymal Features of Breast MDA-MB-453 Cancer Cells. <i>Endocrine Research</i> , 2022, 47, 64-79.	0.6	4

#	ARTICLE	IF	CITATIONS
656	New insights into the discovery of drugs for triple-negative breast cancer metastasis. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 365-376.	2.5	3
657	Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. <i>Cancers</i> , 2022, 14, 1253.	1.7	69
658	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. <i>Nature Communications</i> , 2022, 13, 896.	5.8	46
659	Estrogen receptor beta repurposes EZH2 to suppress oncogenic NF κ B/p65 signaling in triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 20.	2.3	9
660	Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1238.	1.7	7
661	Molecular profiling leading to personalized treatment in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 0, , 1.	0.3	1
662	The Transcriptomic Portrait of Locally Advanced Breast Cancer and Its Prognostic Value in a Multi-Country Cohort of Latin American Patients. <i>Frontiers in Oncology</i> , 2022, 12, 835626.	1.3	1
663	Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs. <i>ACS Nano</i> , 2022, 16, 5184-5232.	7.3	32
664	Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 21-35.	1.1	4
665	Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 95.	3.5	21
666	Gingerenone A Induces Antiproliferation and Senescence of Breast Cancer Cells. <i>Antioxidants</i> , 2022, 11, 587.	2.2	12
668	Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 567-591.	1.9	29
669	Triple-Negative Apocrine Breast Carcinoma Has Better Prognosis despite Poor Response to Neoadjuvant Chemotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1607.	1.0	4
670	Decision Theory versus Conventional Statistics for Personalized Therapy of Breast Cancer. <i>Journal of Personalized Medicine</i> , 2022, 12, 570.	1.1	1
671	NEAT1: Culprit lncRNA linking PIG-C, MSLN, and CD80 in triple-negative breast cancer. <i>Life Sciences</i> , 2022, 299, 120523.	2.0	3
672	Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 1689-1695.	0.8	4
673	Diversified physiological sensory input connectivity questions the existence of distinct classes of spinal interneurons. <i>iScience</i> , 2022, 25, 104083.	1.9	5
674	Overexpression of multiple epidermal growth factor like domains 11 rescues anoikis survival through tumor cells-platelet interaction in triple negative breast Cancer cells. <i>Life Sciences</i> , 2022, 299, 120541.	2.0	2

#	ARTICLE	IF	CITATIONS
675	Are we ready to embrace novel therapeutic targets for women with AR-positive or AR-negative metastatic Triple-Negative Breast Cancer ?. Asia-Pacific Journal of Oncology, 2021, , .	0.2	0
676	Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple- Negative Breast Cancer (TNBC). Current Pharmaceutical Biotechnology, 2022, 23, 1581-1595.	0.9	6
677	Polo-Like Kinase 1(PLK1) Immunohistochemical Expression in Triple Negative Breast Carcinoma: A Probable Therapeutic Target. Asian Pacific Journal of Cancer Prevention, 2021, 22, 3921-3925.	0.5	3
678	Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. Cancers, 2021, 13, 6256.	1.7	6
679	Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 993-1003.	3.2	21
680	Validation of cluster analysis results on validation data: A systematic framework. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery, 2022, 12, .	4.6	29
681	Comparison of the Clinicopathologic Features and T-Cell Infiltration of B7-H3 and B7-H4 Expression in Triple-negative Breast Cancer Subtypes. Applied Immunohistochemistry and Molecular Morphology, 2022, 30, 246-256.	0.6	3
682	Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic Pattern. Frontiers in Oncology, 2022, 12, 830124.	1.3	2
683	Challenges and Gaps in Clinical Trial Genomic Data Management. JCO Clinical Cancer Informatics, 2022, 6, e2100193.	1.0	0
684	PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opinion on Investigational Drugs, 2022, 31, 607-631.	1.9	20
685	Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis. Breast, 2022, 64, 7-18.	0.9	13
686	Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers. Npj Breast Cancer, 2022, 8, 51.	2.3	9
687	Cross-Platform in-silico Analyses Exploring Tumor Immune Microenvironment with Prognostic Value in Triple-Negative Breast Cancer. Breast Cancer: Targets and Therapy, 2022, Volume 14, 85-99.	1.0	3
720	Subclassifying triple-negative breast cancers and its potential clinical utility. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 13-21.	1.4	5
721	Wnt signaling in triple-negative breast cancers: Its roles in molecular subtyping and cancer cell stemness and its crosstalk with non-coding RNAs. Life Sciences, 2022, 300, 120565.	2.0	6
722	Establishing a competing endogenous RNA (ceRNA)-immunoregulatory network associated with the progression of Alzheimer's disease.. Annals of Translational Medicine, 2022, 10, 65.	0.7	0
724	Triple-negative breast cancer - an aggressive subtype of breast cancer. , 2022, , 1-28.		2
725	Different drug delivery approaches in combinational therapy in TNBC. , 2022, , 201-230.		6

#	ARTICLE	IF	CITATIONS
726	<i>ZBED2</i> expression enhances interferon signaling and predicts better survival of estrogen receptor-negative breast cancer patients. <i>Cancer Communications</i> , 2022, , .	3.7	2
727	Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC). <i>Pharmaceuticals</i> , 2022, 15, 542.	1.7	14
728	Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 57.	2.3	11
729	Immunogenomic landscape analyses of immune molecule signature-based risk panel for patients with triple-negative breast cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 670-684.	2.3	10
730	New Prognostic Gene Signature and Immune Escape Mechanisms of Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	3
731	Comparative characterization of 3D chromatin organization in triple-negative breast cancers. <i>Experimental and Molecular Medicine</i> , 2022, 54, 585-600.	3.2	12
732	Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer. <i>Journal of Nanobiotechnology</i> , 2022, 20, 216.	4.2	13
733	Novel biomarkers identified in triple-negative breast cancer through RNA-sequencing. <i>Clinica Chimica Acta</i> , 2022, 531, 302-308.	0.5	2
734	Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 113-123.	1.0	10
735	Triple-Negative Breast Cancer: the Current Aspects of Pathogenesis and Therapies. <i>BioNanoScience</i> , 2022, 12, 1404-1435.	1.5	2
736	Interferon regulatory factor 1 (IRF1) controls the metabolic programmes of low-grade pancreatic cancer cells. <i>Gut</i> , 2023, 72, 109-128.	6.1	2
737	Hormonal Crosstalk Between Thyroid and Breast Cancer. <i>Endocrinology</i> , 2022, 163, .	1.4	11
738	Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer (Review). <i>Oncology Letters</i> , 2022, 24, .	0.8	4
739	Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. <i>Cancer Cell</i> , 2022, 40, 609-623.e6.	7.7	92
741	Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping. <i>Cancers</i> , 2022, 14, 2571.	1.7	2
742	New Achievements for the Treatment of Triple-Negative Breast Cancer. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 5554.	1.3	11
743	Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease. <i>Cancer Letters</i> , 2022, 547, 215775.	3.2	7
744	Unraveling the Role of Guanylate-Binding Proteins (GBPs) in Breast Cancer: A Comprehensive Literature Review and New Data on Prognosis in Breast Cancer Subtypes. <i>Cancers</i> , 2022, 14, 2794.	1.7	2

#	ARTICLE	IF	CITATIONS
746	A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	1
747	GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 721-6.	0.9	3
748	Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. <i>NAR Cancer</i> , 2022, 4, .	1.6	10
751	Classification of triple negative breast cancer by epithelial mesenchymal transition and the tumor immune microenvironment. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
752	Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
753	Global Trends in Research of Androgen Receptor Associated With Breast Cancer From 2011 to 2020: A Scientometric Analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	5
754	Nanotechnological Approaches for the Treatment of Triple-Negative Breast Cancer: A Comprehensive Review. <i>Current Drug Metabolism</i> , 2022, 23, 781-799.	0.7	2
755	Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 557-573.	1.5	5
756	Nano-Based Drug Delivery of Anticancer Chemotherapeutic Drugs Targeting Breast Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2023, 18, 325-342.	0.8	5
757	Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2022, 16, 117822342211075.	0.6	2
759	The evolution of gene expression profiling in breast cancer – A narrative review. <i>The Journal of Clinical and Scientific Research</i> , 2022, .	0.1	0
760	Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 513-535.	1.5	6
761	Deep learning framework for comprehensive molecular and prognostic stratifications of triple-negative breast cancer. <i>Fundamental Research</i> , 2022, , .	1.6	7
762	Rewiring of the Endocrine Network in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
763	Innate immunity as a target for novel therapeutics in triple negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 781-794.	1.9	2
764	Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
765	From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine. <i>Cancers</i> , 2022, 14, 3469.	1.7	5
766	The landscape of systemic therapy for early stage triple-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1291-1303.	0.9	4

#	ARTICLE	IF	CITATIONS
767	Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
768	The development of molecular typing in canine mammary carcinomas. <i>Molecular Biology Reports</i> , 2022, 49, 8943-8951.	1.0	2
769	Immunotherapy and breast cancer: an overview. <i>Current Opinion in Oncology</i> , 2022, 34, 587-594.	1.1	13
770	Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer. <i>Cell Reports Medicine</i> , 2022, 3, 100694.	3.3	24
771	Lipid-Associated Macrophages Are Induced by Cancer-Associated Fibroblasts and Mediate Immune Suppression in Breast Cancer. <i>Cancer Research</i> , 2022, 82, 3291-3306.	0.4	69
773	Evaluation of CD44+/CD24- and Aldehyde Dehydrogenase Enzyme Markers in Cancer Stem Cells as Prognostic Indicators for Triple-Negative Breast Cancer. <i>Cureus</i> , 2022, , .	0.2	0
774	The Utility of SOX10 Immunohistochemical Staining in Breast Pathology. <i>American Journal of Clinical Pathology</i> , 2022, 158, 616-625.	0.4	5
775	c-Kit Induces Migration of Triple-Negative Breast Cancer Cells and Is a Promising Target for Tyrosine Kinase Inhibitor Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8702.	1.8	6
777	Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. <i>Biomarkers</i> , 2022, 27, 764-772.	0.9	5
778	Stat3 Tyrosine 705 and Serine 727 Phosphorylation Associate With Clinicopathological Characteristics and Distinct Tumor Cell Phenotypes in Triple-Negative Breast Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	1
779	Triple negative breast cancer: approved treatment options and their mechanisms of action. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3701-3719.	1.2	13
780	Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
781	p53 missense mutation is associated with immune cell PD-L1 expression in triple-negative breast cancer. <i>Cancer Investigation</i> , 0, , 1-28.	0.6	1
782	Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 341-351.	1.1	7
783	Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 243-252.	1.0	1
784	Triple negative breast cancer: Pitfalls and progress. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	110
785	Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	43
786	Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features. <i>Journal of Zhejiang University: Science B</i> , 2022, 23, 617-624.	1.3	6

#	ARTICLE	IF	CITATIONS
787	BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 263-274.	1.1	5
789	Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer – A Review of Molecular Characterisation, Therapeutic Targets and Future Trends. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
790	Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers. <i>Translational Oncology</i> , 2022, 25, 101511.	1.7	2
791	Racial Disparity in Quadruple Negative Breast Cancer: Aggressive Biology and Potential Therapeutic Targeting and Prevention. <i>Cancers</i> , 2022, 14, 4484.	1.7	5
792	Dandelion extract inhibits triple-negative breast cancer cell proliferation by interfering with glycerophospholipids and unsaturated fatty acids metabolism. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
793	Advancement of cell-penetrating peptides in combating triple-negative breast cancer. <i>Drug Discovery Today</i> , 2022, 27, 103353.	3.2	19
794	Recent advances in therapeutic strategies for triple-negative breast cancer. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	145
795	Chromatin Variants Reveal the Genetic Determinants of Oncogenesis in Breast Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, 12, a041322.	2.9	1
796	PHENOTYPIC CHARACTERISTICS OF ANDROGEN RECEPTOR-POSITIVE CANCER IN THE TRIPLE-NEGATIVE BREAST CANCER GROUP. <i>Ulyanovsk Medico-biological Journal</i> , 2022, , 49-60.	0.0	0
797	Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	35
798	Prognostic Capability of TNBC 3-Gene Score among Triple-Negative Breast Cancer Subtypes. <i>Cancers</i> , 2022, 14, 4286.	1.7	2
799	Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness. <i>Cancers</i> , 2022, 14, 4280.	1.7	17
800	Molecular Classification of Breast Cancer: Relevance and Challenges. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 46-51.	1.2	14
801	Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	19
802	Integrated Bioinformatics Analysis for the Screening of Hub Genes and Therapeutic Drugs in Androgen Receptor-Positive TNBC. <i>Disease Markers</i> , 2022, 2022, 1-18.	0.6	2
803	Integrated bioinformatic analysis of potential biomarkers of poor prognosis in triple-negative breast cancer. <i>Translational Cancer Research</i> , 2022, 11, 3039-3049.	0.4	3
804	Current landscape of personalized clinical treatments for triple-negative breast cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11
805	The roles of small extracellular vesicles as prognostic biomarkers and treatment approaches in triple-negative breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
806	A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers. <i>Scientific Data</i> , 2022, 9, .	2.4	6
807	Emerging Targeted Therapies for Early Breast Cancer. <i>Drugs</i> , 2022, 82, 1437-1451.	4.9	5
808	Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria. <i>Ecancermedicalsecience</i> , 0, 16, .	0.6	2
809	How cancer cells make and respond to interferon-I. <i>Trends in Cancer</i> , 2023, 9, 83-92.	3.8	35
810	Preoperative Systemic Therapy for Breast Cancer. <i>Surgical Clinics of North America</i> , 2023, 103, 201-217.	0.5	4
811	Transcription profiling of feline mammary carcinomas and derived cell lines reveals biomarkers and drug targets associated with metabolic and cell cycle pathways. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
812	Distinct Uroplakin II Staining Pattern in Apocrine Breast Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, 30, 681-686.	0.6	2
813	PD-L1 Gene Polymorphisms rs822336 G>C and rs822337 T>A: Promising Prognostic Markers in Triple Negative Breast Cancer Patients. <i>Medicina (Lithuania)</i> , 2022, 58, 1399.	0.8	2
814	Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 205-214.	1.9	2
815	DeepST: identifying spatial domains in spatial transcriptomics by deep learning. <i>Nucleic Acids Research</i> , 2022, 50, e131-e131.	6.5	34
817	Integrating Genomic Information with Tumor-Immune Microenvironment in Triple-Negative Breast Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 13901.	1.2	1
818	Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple-negative breast cancer. <i>Cancer Medicine</i> , 2023, 12, 5846-5858.	1.3	4
820	Tumor suppressor DEAR1 regulates mammary epithelial cell fate and predicts early onset and metastasis in triple negative breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
821	Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine. <i>Clinical Cancer Research</i> , 2023, 29, 389-400.	3.2	6
822	Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	30
823	Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics. <i>RSC Advances</i> , 2022, 12, 32956-32978.	1.7	7
824	Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches. <i>Breast Cancer</i> , 2023, 30, 167-186.	1.3	3
825	Homologous Recombination Deficiency in Triple-Negative Breast Cancer: Potential Benefit of a New Target. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	0

#	ARTICLE	IF	CITATIONS
826	Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer. , 2023, 241, 108331.		2
827	Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study. Breast Cancer Research and Treatment, 2023, 197, 449-459.	1.1	1
828	Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2022, 23, 14937.	1.8	21
829	EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis. Nature Communications, 2022, 13, .	5.8	24
830	The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. Expert Opinion on Investigational Drugs, 2022, 31, 1203-1226.	1.9	1
832	â€˜Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical researchâ€™. Expert Opinion on Investigational Drugs, 2022, 31, 1291-1310.	1.9	2
833	Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles. Human Genomics, 2022, 16, .	1.4	2
834	Update on tripleâ€negative breast cancersâ€“â€highlighting subtyping update and treatment implication. Histopathology, 2023, 82, 17-35.	1.6	13
835	Gene expression profile analysis to discover molecular signatures for early diagnosis and therapies of triple-negative breast cancer. Frontiers in Molecular Biosciences, 0, 9, .	1.6	4
836	Immune subtype identification and multi-layer perceptron classifier construction for breast cancer. Frontiers in Oncology, 0, 12, .	1.3	3
837	RNA interference: Promising approach for breast cancer diagnosis and treatment. Cell Biology International, 2023, 47, 833-847.	1.4	4
838	A Clinical Cognizance of Molecular and Pathological Diagnostic Approach of TNBC. , 2023, , 26-46.		0
839	Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review. Technology in Cancer Research and Treatment, 2023, 22, 153303382211452.	0.8	6
840	Recent Advances in Understanding the Roles of RNA Binding Proteins in Breast Cancer Pathogenesis. Advances in Clinical Medicine, 2022, 12, 11780-11786.	0.0	0
841	Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers. Cancers, 2023, 15, 403.	1.7	3
842	Rapid identification of breast cancer subtypes using micro-FTIR and machine learning methods. Applied Optics, 2023, 62, C80.	0.9	8
843	Etiological Insights into TNBC and their Related Catastrophic Risks. , 2023, , 1-25.		0
844	Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. Cancers, 2023, 15, 321.	1.7	21

#	ARTICLE	IF	CITATIONS
845	Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	13
846	The relevance between hypoxia-dependent spatial transcriptomics and the prognosis and efficacy of immunotherapy in claudin-low breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
847	Molecular Sub-Typing and Exploration of Key Signalling Pathways Involved in Complicating the Disease. , 2023, , 47-72.		1
848	Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer. <i>Pharmaceutics</i> , 2023, 15, 246.	2.0	7
849	Early Triple-Negative Breast Cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression. <i>Modern Pathology</i> , 2023, 36, 100056.	2.9	2
850	Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
851	Pre-Clinical and Clinical Evidence of Recent Therapeutic Trends and Spotting Possibility of Cure in Near Future. , 2023, , 73-98.		0
853	Nucleolin aptamer conjugated MSNPs-PLR-PEG multifunctional nanoconstructs for targeted co-delivery of anticancer drug and siRNA to counter drug resistance in TNBC. <i>International Journal of Biological Macromolecules</i> , 2023, 229, 600-614.	3.6	10
854	Inhibition of WNT signaling by conjugated microRNA nano-carriers: A new therapeutic approach for treating triple-negative breast cancer a perspective review. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 182, 103901.	2.0	4
855	Correlation of TROP-2 expression with clinical pathological characteristics and outcome in triple-negative breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
856	Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer. <i>Cancers</i> , 2023, 15, 233.	1.7	4
857	Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. <i>Journal of Clinical Medicine</i> , 2023, 12, 953.	1.0	12
858	Overexpression of PKMYT1 associated with poor prognosis and immune infiltration may serve as a target in triple-negative breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
859	Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3245.	1.8	0
860	Introduction to Breast Cancer. , 2023, , 1-22.		1
861	Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low. <i>Breast Cancer Research</i> , 2023, 25, .	2.2	6
862	Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer. <i>Oncologist</i> , 0, , .	1.9	0
863	Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy. <i>Cancers</i> , 2023, 15, 2194.	1.7	0

#	ARTICLE	IF	CITATIONS
864	A Focus on the Synergy of Radiomics and RNA Sequencing in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7214.	1.8	1
866	Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114648.	2.5	1
867	Molecular genetic clusters of triple-negative breast cancer and their prognostic significance. <i>Kazan Medical Journal</i> , 2023, 104, 198-206.	0.1	0
869	A novel fatty-acid metabolism-based classification for triple negative breast cancer. <i>Aging</i> , 0, , .	1.4	0
870	Identification of STAT5B as a biomarker associated with prognosis and immune infiltration in breast cancer. <i>Medicine (United States)</i> , 2023, 102, e32972.	0.4	0
871	Artificial intelligence: opportunities and challenges in the clinical applications of triple-negative breast cancer. <i>British Journal of Cancer</i> , 2023, 128, 2141-2149.	2.9	7
873	Identification of Altered Transcripts and Pathways in Triple Negative Breast Cancer. <i>Proceedings of the Latvian Academy of Sciences</i> , 2023, 77, 33-40.	0.0	0
875	Inter-Relationship of Ki-67 and Triple-Negative Breast Cancer. , 0, , .		0
876	Convolutional neural network for biomarker discovery for triple negative breast cancer with RNA sequencing data. <i>Heliyon</i> , 2023, 9, e14819.	1.4	0
877	Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. <i>Cell Research</i> , 2023, 33, 389-402.	5.7	13
878	Aptamer-Based Strategies to Boost Immunotherapy in TNBC. <i>Cancers</i> , 2023, 15, 2010.	1.7	5
879	The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelialâ€“Mesenchymal Transition. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6422.	1.8	1
880	Crosstalk between triple negative breast cancer and microenvironment. <i>Oncotarget</i> , 2023, 14, 284-293.	0.8	2
881	Comprehensive analysis of glycolysis mediated pattern clusters and immune infiltration characterization of tumor microenvironment in triple-negative breast cancer. <i>Heliyon</i> , 2023, 9, e15175.	1.4	0
882	Altered Expression of CYSLTR1 is Associated With Adverse Clinical Outcome in Triple Negative Breast Tumors: An <i>In Silico</i> Approach. <i>The Journal of Breast Health</i> , 2023, 19, 148-158.	0.4	0
883	Exploring the mechanism of an active ingredient of ginger, dihydrocapsaicin, on triple negative breast cancer based on network pharmacology and <i>inÂvitro</i> experiments. <i>Oncology Letters</i> , 2023, 25, .	0.8	1
884	Development of Cyclic Peptides Targeting the Epidermal Growth Factor Receptor in Mesenchymal Triple-Negative Breast Cancer Subtype. <i>Cells</i> , 2023, 12, 1078.	1.8	2
885	Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far. <i>OncoTargets and Therapy</i> , 0, Volume 16, 235-247.	1.0	3

#	ARTICLE	IF	CITATIONS
886	Calcifications in triple-negative breast cancer: Molecular features and treatment strategies. Npj Breast Cancer, 2023, 9, .	2.3	0
887	Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches. Current Treatment Options in Oncology, 2023, 24, 628-643.	1.3	15
922	The potential roles of lncRNA TINCR in triple negative breast cancer. Molecular Biology Reports, 0, , .	1.0	0
940	KDM4 Demethylases: Structure, Function, and Inhibitors. Advances in Experimental Medicine and Biology, 2023, , 87-111.	0.8	0
951	Introduction to molecular testing in human disease. , 2024, , 1-12.		0
954	Emerging treatment approaches for triple-negative breast cancer. , 2024, 41, .		1
966	Invasive Carcinomas of the Breast. , 2024, , 191-264.		0
970	A Closer Look at the Androgen Receptor (AR)- positive and AR-negative Metastatic Triple-Negative Breast Cancer: Can We Apply Novel Targeted Therapeutics?. , 2023, , 22-38.		0
976	Markers and Immunoprofile of Breast Tumors. , 2023, , 99-115.		0